Bioasis Technologies Inc.
OTC: BIOAF0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Other OTC
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Deborah Ann Rathjen
- Employees
- 4
- Headquarters
- New Haven, United States
- IPO year
- 2010
- Market cap
- $7.9K
- Website
- https://www.bioasis.us
Loading BIOAF…
Loading profile data…Frequently asked questions about BIOAF
What does Bioasis Technologies Inc. (BIOAF) do?
Bioasis Technologies Inc. is a developing biopharmaceutical enterprise dedicated to the discovery and advancement of treatments and diagnostic tools for various neurological conditions. Central to its strategy is the proprietary xB3 platform, an innovative technology designed to overcome the blood-brain barrier (BBB) and effectively deliver ther...
Where does BIOAF trade?
Bioasis Technologies Inc. (BIOAF) trades on the Other OTC.
What sector is BIOAF in?
Bioasis Technologies Inc. (BIOAF) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Bioasis Technologies Inc.?
Deborah Ann Rathjen is the chief executive officer of Bioasis Technologies Inc. (BIOAF).
Where is Bioasis Technologies Inc. headquartered?
Bioasis Technologies Inc. is headquartered in United States.
Does BIOAF pay a dividend?
Bioasis Technologies Inc. (BIOAF) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did BIOAF go public?
Bioasis Technologies Inc. (BIOAF) completed its initial public offering in 2010.